20 May 2013
Keywords: berlex, ultravist, approved, usa, launch, july, schering
Article | 22 May 1995
Schering AG subsidiary Berlex Laboratories has been granted marketing clearance for Ultravist (iopromide), an injectable, iodinated nonionic contrast agent for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.